首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1673492

雙特異性抗體市場：全球市場機會、劑量、專利、定價、銷售、臨床試驗趨勢（2030年）

Global Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030

出版日期: 2025年03月01日 | 出版商:

KuicK Research | 英文 1000 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

在持續創新和病患接受度不斷提高的推動下，雙特異性抗體已成為醫藥市場上最有前景和商業上最成功的標靶方法之一。這一驚人成長的關鍵驅動因素是雙特異性抗體臨床試驗數量的急劇增加，將從2015年的不到 100個增加到2025年的650 多個。這項進步將為藥物開發商、臨床研究組織、醫生和患者等多方利害關係人帶來重大利益。截至2025年 3月，已有 17 種雙特異性抗體在主要市場獲得批准，累計銷售額超過 350億美元，而2015年首個雙特異性抗體獲得批准時銷售額為 7,700萬美元。

雙特異性抗體市場預計在2024年達到約 120億美元，到2030年將呈指數成長至 500億美元。該成長軌跡顯示對能夠滿足未滿足的醫療需求的創新生物製劑的需求不斷增加。值得注意的是，Hemlibra 和 Vabysmo 已成為全球雙特異性抗體市場的主要參與者，合計佔總銷售額的75%以上。Roche開發的雙特異性抗體Hemlibra用於治療血友病A，同樣由Roche開發的Bavismo用於治療黃斑部病變和黃斑水腫。預計到2024年，這兩種藥物的銷售額將超過 40億美元，成為各自治療領域的主要進入者，並鞏固Roche在雙特異性抗體市場的領導地位。

目前還有幾種雙特異性抗體審查核准。值得注意的是，美國 FDA 和歐洲藥品管理局（EMA）審查一種開發雙特異性抗體 Linvoseltamab，用於治療多發性骨髓瘤。另一個有希望的候選藥物Odronextamab目前接受 FDA 審查，用於治療多種血液系統惡性腫瘤。這些發展凸顯了雙特異性抗體研究的進展及其徹底改變癌症治療的潛力。

截至2025年 3月，已有 600 多種雙特異性抗體臨床試驗中，證明了該類治療在多個治療領域的巨大潛力。美國在研發和銷售方面繼續成為雙特異性抗體的最大市場，反映了其在醫藥創新和醫療保健支出方面的領導地位。

本報告研究了全球雙特異性抗體市場，並概述了市場以及藥物趨勢、臨床試驗趨勢、區域趨勢以及參與市場的公司的競爭格局。

ABL Bio
Abzyme Therapeutics
Affimed Therapeutics
Akeso Biopharma
Alligator Bioscience
Amgen
Antibody Therapeutics
APITBIO
Aptevo Therapeutics
Astellas Pharma
AstraZeneca
BioAtla
Biosion
Biotheus
BJ Bioscience
EpimAb Biotherapeutics
FutureGen Biopharmaceutical
Genentech
Genmab
Gensun Biopharma
Harbour BioMed
IGM Biosciences
I-MAB Biopharma
ImmuneOnco Biopharma
Innovent Biologics
Invenra
Janssen Research & Development
Kenjockety Biotechnology
LaNova Medicines Limited
Light Chain Bioscience
Linton Pharm
Lyvgen Biopharma
MacroGenics
Merus
NovaRock Biotherapeutics
Pfizer
Phanes Therapeutics
Prestige BioPharma
Regeneron Pharmaceuticals
Revitope
Roche
Virtuoso Therapeutics
Xencor
Y-Biologics
Zhejiang Shimai Pharmaceutical
Zymeworks

簡介目錄圖表

Global Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030 Report findings & Highlights:

Global & Regional Market Size, Clinical Trends Insight
Global Bispecific Antibodies Sales Opportunity US$ 50 Billion By 2030
Global Bispecific Antibodies Sales Surpassed US$ 11 Billion In 2024
17 Bispecific Antibodies Approved Across Key Markets
Approved Antibodies Dosage, Patent, Pricing & Sales Insight
Comprehensive Insight On More than 600 Bispecific Antibodies In Clinical Trials
Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

Bispecific antibodies have emerged as one of the most promising and commercially successful targeting approaches in the pharmaceutical market, driven by continuous innovations and growing patient acceptance. A major factor contributing to this phenomenal growth is the exponential increase in the number of clinical trials for bispecific antibodies, which has surpassed 650 in 2025 from less than 100 in 2015. This progress has significantly benefited multiple stakeholders like drug developers, clinical research organizations, physicians, and patients. As of March 2025, 17 bispecific antibodies have been approved across key markets, with cumulative sales exceeding US$ 35 Billion as compared to US$ 77 Million in 2015 when the first bispecific antibody was approved.

The bispecific antibody market reached approximately US$ 12 billion in 2024, with projections by Kuick Research suggesting that this market will surge to US$ 50 billion by 2030. This growth trajectory highlights the increasing demand for innovative biologics that can address unmet medical needs. Notably, Hemlibra and Vabysmo have emerged as major contributors to the global bispecific antibodies market, collectively accounting for over 75% of the total sales. Hemlibra, a bispecific antibody developed by Roche, is used to treat hemophilia A, while Vabysmo, also developed by Roche, is a treatment for macular degeneration and macular edema. Both drugs saw sales surpassing US$ 4 Billion in 2024, emerging as key players in their respective therapeutic areas and solidifying Roche's leadership in the market for bispecific antibodies.

There are also several bispecific antibodies currently under regulatory review. Notably, Linvoseltamab, an investigational bispecific antibody, is undergoing review by the US FDA and the European Medicines Agency (EMA) for the treatment of multiple myeloma. Another promising candidate, Odronextamab, is currently under FDA review for the treatment of various hematologic malignancies. These developments underscore the ongoing progress in bispecific antibody research and their potential to revolutionize cancer treatment.

As of March 2025, more than 600 bispecific antibodies are currently undergoing clinical trials, demonstrating the immense potential of these therapeutics across multiple therapeutic areas. The US remains the largest market for bispecific antibodies in terms of both research and development (R&D) and sales, reflecting the country's leadership in pharmaceutical innovation and healthcare spending.

Leading players in the bispecific antibody market include Roche, Gilead, Amgen, Pfizer, Johnson & Johnson (Janssen), and others. These companies are at the forefront of developing innovative bispecific therapies, with a focus on oncology and other high-need areas. For example, Roche has leveraged its expertise in biologics to bring to market Hemlibra and Vabysmo, while Amgen is advancing bispecific T-cell engagers for cancer immunotherapy.

In addition to these leading companies, there have been significant regulatory designations granted to bispecific antibodies, enhancing the overall market landscape. Ivonescimab, a PD-1 x VEGF bispecific antibody developed by Akeso, received FDA Fast Track Designation in October 2024 for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations in the second-line or beyond setting. This designation accelerates the development process and highlights the growing interest in bispecific antibodies for treating cancer. Akeso is collaborating with Summit Therapeutics in the US and other countries to develop Ivonescimab.

Additionally, Invenra's Novel Antibody INV724 has received both Rare Pediatric Disease and Orphan Drug Designations from the US FDA for the treatment of neuroblastoma, a rare and aggressive cancer affecting children. INV724 targets the GD2 and B7-H3 antigens and has shown promise in early-stage clinical trials, offering hope for more effective treatments for pediatric cancers.

In conclusion, the bispecific antibody market is poised for substantial growth, driven by increasing approvals, ongoing clinical trials, and strong regulatory support. With major players like Roche, Gilead, Amgen, and Pfizer leading the charge, and promising candidates undergoing review, bispecific antibodies are set to transform the landscape of modern therapeutics. The market's rapid expansion from US$ 12 Billion in 2024 to an expected US$ 50 Billion by 2030, reflects the increasing recognition of bispecific antibodies as key solutions for treating complex and life-threatening diseases.

Table of Contents

1. Introduction To Bispecific Antibody

1.1 Overview
1.2 Clinical Advancement of Bispecific Antibodies

2. Bispecific Antibodies Combination Strategies

2.1 Chemotherapy
2.2 Targeted Therapy
2.3 Immunotherapies
2.4 Radiotherapy

3. Commercially Approved Bispecific Antibodies Insight

3.1 Company, Indication, Location & MOA
3.2 Bispecific Antibodies Granted FDA & EMA Designations

4. Bispecific Antibodies Proprietary Platforms

5. Global & Regional Bispecific Antibody Market Outlook

5.1 Yearly & Quarterly Sales Insight (2020 to 2024)
5.2 Approved Bispecific Antibodies Reimbursement Policy
5.3 Global Bispecific Antibody Market Forecast 2030

6. Global Bispecific Antibody Market Trends By Region

6.1 Japan
6.2 South Korea
6.3 US
6.4 Europe
6.5 China
6.6 UK
6.7 Australia
6.8 Canada
6.9 Latin America

7. Global Bispecific Antibodies Research & Market Trends By Indications

7.1 Lymphoma
7.2 Multiple Myeloma
7.3 Leukemia
7.4 Lung Cancer
7.5 Melanoma
7.6 Gastrointestinal Cancers
7.7 Other Cancers
7.8 Blood Disorders
7.9 Autoimmune & Inflammatory Diseases
7.10 Microbial Diseases
7.11 Ocular Diseases

8. Blincyto - Clinical, Patent, Pricing & Sales Insight

8.1 Overview & Patent Insight
8.2 Pricing & Dosage Analysis
8.3 Sales Analysis

9. Hemlibra - Clinical, Patent, Pricing & Sales Insight

9.1 Overview
9.2 Pricing & Dosage Insight
9.3 Sales Analysis

10. Rybrevant - Clinical, Patent & Pricing Insight

10.1 Overview
10.2 Pricing & Dosage Insight

11. Vabysmo - Clinical, Patent, Pricing & Sales Insight

11.1 Overview
11.2 Pricing & Dosage Insight
11.3 Sales Analysis

12. Lunsumio - Clinical, Patent, Pricing & Sales Insight

12.1 Overview & Patent Insight
12.2 Pricing & Dosage Insight
12.3 Sales Analysis

13. Kaitani - Clinical & Sales Insight

14. Tecvayli - Clinical, Patent & Pricing Insight

14.1 Overview & Patent Insight
14.2 Pricing & Dosage Insight
14.3 Sales Analysis

15. Columvi - Clinical, Patent, Pricing & Sales Insight

15.1 Overview & Patent Insight
15.2 Pricing & Dosage Insight
15.3 Sales Analysis

16. Epkinly - Clinical, Patent, Pricing & Sales Insight

16.1 Overview
16.2 Pricing & Dosage Insight
16.3 Sales Analysis

17. Talvey - Clinical, Patent & Pricing Insight

17.1 Overview & Patent Insight
17.2 Pricing & Dosage Insight

18. Elrexfio - Clinical, Patent & Pricing Insight

18.1 Overview
18.2 Pricing & Dosage Insight
18.3 Sales Analysis

19. Imdelltra - Clinical, Patent, Pricing & Sales Insight

19.1 Overview & Patent Insight
19.2 Pricing & Dosage Insight
19.3 Sales Analysis

20. Ivonescimab - Clinical Insight

21. Ordspono - Clinical & Sales Insight

21.1 Overview
21.2 Sales Analysis

22. Ziihera - Clinical, Pricing & Sales Insight

22.1 Overview
22.2 Pricing & Dosage
22.3 Sales Insight

23. Bizengri - Clinical, Patent, Pricing & Sales Insight

23.1 Overview
23.2 Dosing & Pricing

24. Korjuny - Clinical Insight

25. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

25.1 Research
25.2 Preclinical
25.3 Phase-I
25.4 Phase-I/II
25.5 Phase-II
25.6 Phase-II/III
25.7 Phase-III
25.8 Preregistration
25.9 Registered

26. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

27. Competitive Landscape

27.1 ABL Bio
27.2 Abzyme Therapeutics
27.3 Affimed Therapeutics
27.4 Akeso Biopharma
27.5 Alligator Bioscience
27.6 Amgen
27.7 Antibody Therapeutics
27.8 APITBIO
27.9 Aptevo Therapeutics
27.10 Astellas Pharma
27.11 AstraZeneca
27.12 BioAtla
27.13 Biosion
27.14 Biotheus
27.15 BJ Bioscience
27.16 EpimAb Biotherapeutics
27.17 FutureGen Biopharmaceutical
27.18 Genentech
27.19 Genmab
27.20 Gensun Biopharma
27.21 Harbour BioMed
27.22 IGM Biosciences
27.23 I-MAB Biopharma
27.24 ImmuneOnco Biopharma
27.25 Innovent Biologics
27.26 Invenra
27.27 Janssen Research & Development
27.28 Kenjockety Biotechnology
27.29 LaNova Medicines Limited
27.30 Light Chain Bioscience
27.31 Linton Pharm
27.32 Lyvgen Biopharma
27.33 MacroGenics
27.34 Merus
27.35 NovaRock Biotherapeutics
27.36 Pfizer
27.37 Phanes Therapeutics
27.38 Prestige BioPharma
27.39 Regeneron Pharmaceuticals
27.40 Revitope
27.41 Roche
27.42 Virtuoso Therapeutics
27.43 Xencor
27.44 Y-Biologics
27.45 Zhejiang Shimai Pharmaceutical
27.46 Zymeworks

簡介目錄圖表

List of Figures

Figure 1-1: Bispecific Antibodies - Advantages
Figure 2-1: Antibody-Chemotherapy Combination - Advantages
Figure 2-2: Antibody-Chemotherapy Combination - Impending Challenges
Figure 3-1: Blincyto - Mechanism of Action
Figure 3-2: Hemlibra - Mechanism of Action
Figure 3-3: Rybrevant - Mechanism of Action
Figure 3-4: Regulatory Designations - Benefits
Figure 4-1: Multiclonics - Distinctive Characteristics
Figure 4-2: Biclonics - Format
Figure 4-3: ADAPTIR Bispecific Structure
Figure 4-4: ADAPTIR-FLEX
Figure 4-5: BEAT Platform - Multispecific Antibodies
Figure 4-6: FIT-Ig - Proprietary Bispecific Platform
Figure 4-7: BiClone format
Figure 4-8: BioAtla CABs - Features
Figure 4-9: BioAtla CABs - Benefits
Figure 4-10: IMBiologic Bispecific Antibodies - Strategy
Figure 4-11: IMBiologic Bispecific Antibodies - Mechanism of Action
Figure 4-12: Novel HBICE
Figure 4-13: HBICE - Mechanism of Action 1
Figure 4-14: HBICE - Mechanism of Action 2
Figure 4-15: Phanes Therapeutics - PACbody Platform
Figure 4-16: Phanes Therapeutics - SPECpair Platform
Figure 4-17: Phanes Therapeutics - ATACCbody
Figure 4-18: Numab Therapeutics - Technology
Figure 4-19: Grabody I Platform - Mechanism of Action
Figure 4-20: Grabody I Platform - Mechanism of Action
Figure 4-21: 3-Step DuoBody Production Process
Figure 4-22: DuoHexaBody Molecules - Schematic
Figure 4-23: iTAb - Patented Structure
Figure 4-24: iTAb - Mechanism of Action
Figure 4-25: Synimmune - Proprietary Bispecific Antibody Format
Figure 4-26: BiTE - Structure
Figure 4-27: BiTE Molecule
Figure 4-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 4-29: ALiCE - Characteristics
Figure 4-30: ALiCE - Schematic Diagram & Mechanism of Action
Figure 4-31: Abz2 Bispecific Platform
Figure 4-32: Abz2 Bispecifics - Benefits
Figure 4-33: Neo-X-Prime Bispecific Mechanism
Figure 4-34: B-Body Bispecific Antibody - Structre
Figure 4-35: xLinkBsAb - Structure
Figure 4-36: PrecisionGATE Bispecific Antibody - Structure
Figure 5-1: Global - Annual Bispecific Antibody Market (US$ Million), 2020-2024
Figure 5-2: Global - Annual Bispecific Antibodies Market By Drugs (US$ Million), 2024
Figure 5-3: Global - Bispecific Antibodies Market Shares by Drugs (%), 2024
Figure 5-4: Global - Quarterly Bispecific Antibody Market (US$ Million), 2024
Figure 5-5: Global - Annual Bispecific Antibody Market By Region (US$ Million), 2024
Figure 5-6: Global - Bispecific Antibody Market Shares By Region (%), 2024
Figure 5-7: US -Bispecific Antibody Market (US$ Million), 2020-2024
Figure 5-8: US - Quarterly Bispecific Antibodies Market (US$ Million), 2024
Figure 5-9: US - Quarterly Bispecific Antibodies Market (US$ Million),2023
Figure 5-10: ROW -Bispecific Antibody Market Value (US$ Million), 2020-2024
Figure 5-11: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2024
Figure 5-12: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2023
Figure 5-13: Global - Bispecific Antibodies Market By Drug (US$ Million), 2023
Figure 5-14: Global - Bispecific Antibodies Market Shares By Drugs (%), 2023
Figure 5-15: Global - Quarterly Bispecific Antibody Market (US$ Million), 2023
Figure 5-16: Global - Bispecific Antibody Market By Region (US$ Million), 2023
Figure 5-17: Global - Bispecific Antibody Market Shares By Region (%), 2023
Figure 5-18: Blincyto - Total Treatment Cost & Reimbursement Cost
Figure 5-19: Blincyto - In Pocket & Out of Pocket Cost of Treatment
Figure 5-20: Hemlibra - Total Treatment Cost & Reimbursement Cost
Figure 5-21: Hemlibra - In Pocket & Out Of Pocket Cost Of Treatment
Figure 5-22: Rybrevant - Maximum Coverage By Medicaid (US$), 2023
Figure 5-23: Rybrevant - Maximum Coverage By Private Insurance Coverage (US$), 2021
Figure 5-24: Vabysmo - Total Treatment Cost & Reimbursement Cost
Figure 5-25: Vabysmo - In Pocket & Out Of Pocket Cost Of Treatment
Figure 5-26: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2025 - 2030
Figure 6-1: US - Bispecific Antibodies Approval
Figure 7-1: Bispecific Antibodies - Advantages
Figure 7-2: HX009-II-02 Phase 1/2 Study - Initiation & Completion Year
Figure 7-3: Bispecific Antibodies - Future Opportunities in Melanoma
Figure 7-4: Mim8 Phase 3 (NCT05878938) Study - Initiation & Completion Year
Figure 7-5: NXT007 Phase 1/2 (NCT05987449) Study - Initiation & Completion Year
Figure 7-6: HMB-001 Phase 1/2 (NCT06211634) Study - Initiation & Completion Year
Figure 8-1: Blincyto - Approval Year By Region
Figure 8-2: Blincyto - Patent Filing & Expiration Year
Figure 8-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 8-4: Blincyto - Duration Of Treatment Phase & Resting Phase In Induction & Consolidation Cycles For Treatment Of MRD-Positive B-Cell Precursor (Days)
Figure 8-5: Blincyto - Recommended Number Of Induction & Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL
Figure 8-6: Blincyto - Duration Of Single Induction, Consolidation, Continued Cycle & Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)
Figure 8-7: Global - Blincyto Sales (US$ Million), 2020-2024
Figure 8-8: Global - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-9: Global - Blincyto Sales Quaterly (US$ Million), 2023
Figure 8-10: Blincyto - Sales By Region (US$ Million), 2024
Figure 8-11: Blincyto - Sales By Region (%), 2024
Figure 8-12: Blincyto - Sales By Region (US$ Million), 2023
Figure 8-13: Global - Blincyto Sales By Region (%), 2023
Figure 8-14: US - Blincyto Sales ((US$ Million), 2020-2024
Figure 8-15: US - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-16: US - Blincyto Sales Quaterly (US$ Million), 2023
Figure 8-17: ROW - Blincyto Sales (US$ Million), 2020-2024
Figure 8-18: ROW - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-19: ROW - Blincyto Sales Quaterly (US$ Million), 2023
Figure 9-1: Hemlibra - Approval Years By Region
Figure 9-2: Hemlibra - Cost per Unit & Supply of 30 mg/mL Subcutaneous Injection Of Different Volumes (US$), March'2025
Figure 9-3: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection Of Different Volumes (US$), March'2025
Figure 9-4: Hemlibra - Recommended Loading & Maintenance Dose For Treatment Of Hemophilia (mg/kg/Week)
Figure 9-5: Global - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-6: Global - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-7: Global - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-8: US - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-9: US - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-10: US - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-11: Europe - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-12: Europe - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-13: Europe - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-14: Japan - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-15: Japan - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-16: Japan - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-17: ROW - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-18: ROW - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-19: ROW - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-20: Global - US v/s ex-US Sales (US$ Million), 2024
Figure 9-21: Global - Hemlibra Annual Sales By Region (US$ Million), 2024
Figure 9-22: Global - Hemlibra Sales By Region (%), 2024
Figure 9-23: Global - US v/s Ex-US Sales (US$ Million), 2023
Figure 9-24: Global - Hemlibra Annual Sales By Region (US$ Million), 2023
Figure 9-25: Global - Hemlibra Sales By Region (%), 2023
Figure 10-1: Rybrevant - Patent Filing & Expiration Year
Figure 10-2: Rybrevant - Price Per Unit & Supply Of Intravenous Solution (US$), March'2025
Figure 10-3: Rybrevant - Recommended Dose Per Cycle By Body Weight (mg)
Figure 10-4: Rybrevant - Dose Reduction In Patients With Weight Less Than 80 kg (mg)
Figure 10-5: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 11-1: Vabysmo - Approval Year By Region
Figure 11-2: Rybrevant - Patent Filing & Expiration Year
Figure 11-3: Vabysmo - Price Per Unit & Supply Of Intravitreal Solution (US$), March'2025
Figure 11-4: Global - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-5: Global - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-6: Global - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-7: US - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-8: US - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-9: US - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-10: Europe - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-11: Europe - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-12: Europe - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-13: Japan - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-14: Japan - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-15: Japan - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-16: ROW - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-17: ROW - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-18: ROW - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-19: Global - Vabysmo US v/s Ex-US Sales (US$ Million), 2024
Figure 11-20: Global - Vabysmo Annual Sales by Region (US$ Million), 2024
Figure 11-21: Global - Vabysmo Sales By Region (%), 2024
Figure 11-22: Global - Vabysmo US v/s Ex-US Sales (US$ Million), 2023
Figure 11-23: Global - Vabysmo Annual Sales By Region (US$ Million), 2023
Figure 11-24: Global - Vabysmo Sales By Region (%), 2023
Figure 12-1: Lunsumio - Approval Years By Region
Figure 12-2: US - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2025
Figure 12-3: EU - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2025
Figure 12-4: Global - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-5: Global - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-6: Global - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-7: US - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-8: US - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-9: US - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-10: Europe - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-11: Europe - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-12: Europe - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-13: ROW - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-14: ROW - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-15: Lunsumio - US v/s Ex-US Sales (US$ Million), 2024
Figure 12-16: Global - Lunsumio Annual Sales By Region (US$ Million), 2024
Figure 12-17: Global - Lunsumio Sales By Region (%), 2024
Figure 12-18: Global - US v/s Ex-US Sales (US$ Million), 2023
Figure 12-19: Global - Lunsumio Annual Sales By Region (US$ Million), 2023
Figure 12 20: Global - Lunsumio Sales By Region (%), 2023
Figure 13-1: China - Kaitani Sales (US$ Million), 2022-2023
Figure 13-2: China - Kaitani Sales (US$ Million), H1-H2'2023
Figure 14-1: Tecvayli - Approval Years by Region
Figure 14-2: Tecvayli - Patent Acceptance & Expiration Year
Figure 14-3: US - Cost Per Unit & Supply Of Tecvayli Subcutaneous Solution (US$), March'2025
Figure 14-4: EU - Cost of Supply Of Tecvayli Subcutaneous Solution (US$), March'2025
Figure 14-5: Global - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-6: Global - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-7: Global - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-8: US - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-9: US - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-10: US - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-11: ROW - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-12: ROW - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-13: ROW - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-14: Tecvayli - US v/s Ex-US Sales (US$ Million), 2024
Figure 14-15: Tecvayli - US v/s Ex-US Sales (%), 2024
Figure 14-16: Tecvayli - US v/s Ex-US Sales (US$ Million), 2023
Figure 14-17: Tecvayli - US v/s Ex-US Sales (%), 2023
Figure 15-1: Columvi - Approval Year By Region
Figure 15-2: US - Price Per Unit & Supply Of Columvi Intravenous Solution (US$), March'2025
Figure 15-3: EU - Price Of Supply Of Columvi Intravenous Solution (US$), March'2025
Figure 15-4: Global - Columvi Sales (US$ Million), 2023-2024
Figure 15-5: Global - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-6: Global - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-7: US - Columvi Sales (US$ Million), 2023-2024
Figure 15-8: US - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-9: US - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-10: Europe - Columvi Sales (US$ Million), 2023 & 2024
Figure 15-11: Europe - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-12: Europe - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-13: ROW - Columvi Sales (US$ Million), 2023 & 2024
Figure 15-14: ROW - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-15: ROW - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-16: Global - Columvi US v/s Ex-US Sales (US$ Million), 2024
Figure 15-17: Global - Columvi Annual Sales By Region (US$ Million), 2024
Figure 15-18: Global - Columvi Sales By Region (%), 2024
Figure 15-19: Global - Columvi US v/s Ex-US Sales (US$ Million), 2023
Figure 15-20: Global - Columvi Annual Sales By Region (US$ Million), 2023
Figure 15-21: Global - Columvi Sales By Region (%), 2023
Figure 16-1: Epkinly - Approval Year By Region
Figure 16-2: US - Cost Per Unit & Supply Of Epkinly Subcutaneous Solution (US$), March'2025
Figure 16-3: EU - Cost Of Supply Of Epkinly Subcutaneous Solution (US$), March'2025
Figure 16-4: Global - Epkinly Sales (US$ Million), 2023 & 2024
Figure 16-5: Global - Epkinly Sales Reported By Genmab (US$ Million), 2023 & 2024
Figure 16-6: Global - Epkinly Sales Reported By AbbVie (US$ Million), 2023 & 2024
Figure 16-7: Global - Epkinly Sales By Company (US$ Million), 2024
Figure 16-8: Global - Epkinly Sales By Company (US$ Million), 2023
Figure 17-1: Talvey - Approval Year By Region
Figure 17-2: Talquetamab - FDA & EMA Designation Year
Figure 17-3: Talvey - Patent Acceptance & Expiration Year
Figure 17-4: US - Price Per Unit & Supply Of Talvey Intravenous Solution (US$), March'2025
Figure 17-5: EU - Price Per Supply Of Talvey Intravenous Solution (US$), March'2025
Figure 18-1: Elrexfio - Approval Year by Region
Figure 18-2: Elranatamab - FDA & EMA Designation Year
Figure 18-3: US - Price Per Unit & Supply Of Elrexfio Subcutaneous Solution (US$), March'2025
Figure 18-4: Global - Elrexfio Sales (US$ Million), 2023 & 2024
Figure 18-5: US - Elrexfio Sales (US$ Million), 2023 & 2024
Figure 18-6: ROW - Elrexfio Sales (US$ Million), 2023 & 2024
Figure 19-1: Imdelltra - Approval Year By Region
Figure 19-2: US - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2025
Figure 19-3: EU - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2025
Figure 19-4: Global - Imdelltra Sales (US$ Million), 2024
Figure 19-5: Global - Imdelltra Sales Quaterly (US$ Million), 2024
Figure 21-1: Global - Ordspono Sales (US$ Million), 2022-2024
Figure 21-2: Global - Ordspono Sales Quaterly (US$ Million), 2024
Figure 22-1: US - Price Per Unit & Supply Of Ziihera (US$), March'2025
Figure 22-2: Global - Ziihera Sales (US$ Million), 2024
Figure 23-1: Zenocutuzumab - Active Patents

List of Tables

Table 2-1: Bispecific Antibody & Chemotherapy Combinations in Clinical Trials
Table 2-2: Bispecific Antibody & Targeted Therapy Combinations in Clinical Trials
Table 2-3: Bispecific Antibody & Immunotherapy Combinations in Clinical Trials
Table 2-4: Bispecific Antibody & Radiotherapy Combinations in Clinical Trials
Table 3-1: Approved Bispecific Antibodies
Table 3-2: US - Bispecific Antibodies with Regulatory Designations
Table 3-3: EU - Bispecific Antibodies with Regulatory Designations
Table 3-4: China - Bispecific Antibodies with Regulatory Designations
Table 5-1: Epkinly - Billing Unit Application For Doses
Table 5-2: Talvey - Coverage Summary
Table 5-3: Talvey - Coding Summary
Table 5-4: Elrexfio - HCPCS Codes
Table 5-5: Elrexfio - HCPCS Modifiers
Table 5-6: Imdelltra - Payer Coverage & Reimbursement Details
Table 5-7: Ziihera - ICD-10-CM Codes
Table 5-8: Ziihera - ICD-10-PCS Codes
Table 6-1: US - Some FDA Designated Bispecific Antibodies
Table 6-2: US - Bispecific Antibodies With Recent IND Clearances
Table 6-3: EU - Bispecific Antibodies in Late Stage Clinical Trials
Table 6-4: Latin America - Bispecific Antibodies in Clinical Trials
Table 7-1: Lymphoma - Bispecific Antibodies in Clinical Trials
Table 7-2: Multiple Myeloma - Bispecific Antibodies in Clinical Trials
Table 7-3: Leukemia - Bispecific Antibodies in Clinical Trials
Table 7-4: Lung Cancer - Bispecific Antibodies in Clinical Trials
Table 7-5: Melanoma - Bispecific Antibodies in Clinical Trials
Table 7-6: Gastrointestinal Cancers - Bispecific Antibodies in Clinical Trials
Table 8-1: Blincyto - Active Patents
Table 8-2: Blincyto - Recommended Dosage & Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL
Table 8-3: Blincyto - Recommended Dosage & Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
Table 8-4: Blincyto - Recommended Dosage & Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
Table 10-1: Rybrevant - Premedication
Table 10-2: Rybrevant - Dose Reductions For Adverse Reactions
Table 10-3: Rybrevant - Recommended Dosage Modifications For Adverse Reactions
Table 12-1: Lunsumio - Recommended Treatment Cycles
Table 12-2: Lunsumio - Recommended Premedications
Table 12-3: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome
Table 14-1: Tecvayli - Dosing Schedule
Table 14-2: Tecvayli - Recommended Dosage Modifications For Adverse Reactions
Table 15-1: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 15-2: Columvi - Premedications To Be Administered
Table 15-3: Columvi - Recommendations For Management Of Cytokine Release Syndrome
Table 15-4: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)
Table 15-5: Columvi - Recommended Dosage Modifications For Other Adverse Reactions
Table 16-1: Epkinly - Dosage Schedule
Table 16-2: Epkinly - Recommendations For Management Of Cytokine Release Syndrome
Table 16-3: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 16-4: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions
Table 17-1: Talvey - Weekly Dosing Schedule
Table 17-2: Talvey - Biweekly Dosing Schedule
Table 17-3: Talvey - Recommendations for Management of CRS
Table 17-4: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 17-5: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)
Table 17-6: Talvey - Recommended Dosage Modifications For Other Adverse Reactions
Table 18-1: Elrexfio - Dosing Schedule
Table 18-2: Elrexfio - Recommendations For Management Of CRS
Table 18-3: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions
Table 22-1: Ziihera - Dosage Modifications For Adverse Reactions
Table 23-1: Bizengri - Premedications Prior To Infusions
Table 23-2: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions